Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018

BACKGROUND: A novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac]) was developed as part of efforts to prevent frequent meningitis outbreaks in the African meningitis belt. The MACV was first used widely and with great success, beginning in December 2010, during initial deployment i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Infect Dis
Auteurs principaux: Bwaka, Ado, Bita, André, Lingani, Clément, Fernandez, Katya, Durupt, Antoine, Mwenda, Jason M, Mihigo, Richard, Djingarey, Mamoudou H, Ronveaux, Olivier, Preziosi, Marie-Pierre
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Supplement Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822965/
https://ncbi.nlm.nih.gov/pubmed/31671448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiz336
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires